TDB, Sapigen Biologix ink agreement to commercialise intranasal COVID-19, RTS, S Malaria vaccine, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

Under the agreement signed, Technology Development Board and Bharat Biotech have pledged support of Rs 200 crore each to create a continuous corpus of Rs 400 crore for development and commercialisation of two novel vaccines –‘Intranasal COVID-19 Vaccine’ and ‘RTS, S Malaria Vaccine’., Under the agreement signed, Technology Development Board and Bharat Biotech have pledged support of Rs 200 crore each to create a continuous corpus of Rs 400 crore for development and commercialisation of two novel vaccines –‘Intranasal COVID-19 Vaccine’ and ‘RTS, S Malaria Vaccine’., , Read More

Leave a Reply

Your email address will not be published. Required fields are marked *